SCHEMBL752066

SCHEMBL752066

CCOc1ccccc1C1NC(=O)CO1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.46
HTR2B P41595 2/20 0.46
HTR2C P28335 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
TSHR P16473 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
LMNA P02545 2/20 0.46
HTT P42858 1/20 0.44
ALDH1A1 P00352 3/20 0.42
MAPT P10636 2/20 0.42
KDM4E B2RXH2 2/20 0.42
GAA P10253 1/20 0.42
RAB9A P51151 1/20 0.42
PAX8 Q06710 1/20 0.42
MAPK1 P28482 1/20 0.42
RECQL P46063 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
SLC6A2 P23975 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4536209 0.72 HCRTR2 (0.45) HTR2AHTR2BHTR2CSMN1; SMN2TSHR
SCHEMBL11302784 0.72 HTR2B (0.55) HTR2AHTR2BHTR2CSMN1; SMN2TSHR
SCHEMBL10668061 0.71 L3MBTL1 (0.72) HTR2AHTR2BHTR2CSMN1; SMN2TSHR
SCHEMBL11098842 0.70 HTR2B (0.54) HTR2AHTR2BHTR2CSMN1; SMN2TSHR
SCHEMBL749617 0.70 L3MBTL1 (0.40) HTR2ALMNAALDH1A1KDM4EGAA
SCHEMBL29144904 0.70 ADRA2A (0.41) HTR2AHTR2BHTR2CALDH1A1KDM4E
SCHEMBL12191228 0.69 SLC6A2 (0.60) HTR2AHTR2BHTR2CNPSR1ALDH1A1
SCHEMBL10396065 0.69 ALDH1A1 (0.32) ALDH1A1GAA
SCHEMBL25575920 0.69 HTR2A (0.46) HTR2AHTR2BHTR2CSMN1; SMN2TSHR
SCHEMBL17747275 0.68 TACR1 (0.41) TSHRLMNAALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430004-B1 NOVEL OXAZOLIDINONE DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2013-07-17 EP disclosed
US-8329706-B2 Oxazolidinone derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-12-11 US disclosed
US-20120101111-A1 NOVEL OXAZOLIDINONE DERIVIATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2012-04-26 US disclosed
EP-2430004-A2 NOVEL OXAZOLIDINONE DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2012-03-21 EP disclosed
WO-2010131192-A2 NOVEL OXAZOLIDINONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2010-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101111-A1 NOVEL OXAZOLIDINONE DERIVIATIVES HCRTR2, HCRTR1, NPY4R HTR2A 210/4885HTR2B 125/4885HTR2C 187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.